[go: up one dir, main page]

WO2004059278A3 - Methods of screening for anti-inflammatory drugs and use thereof - Google Patents

Methods of screening for anti-inflammatory drugs and use thereof Download PDF

Info

Publication number
WO2004059278A3
WO2004059278A3 PCT/IL2003/001116 IL0301116W WO2004059278A3 WO 2004059278 A3 WO2004059278 A3 WO 2004059278A3 IL 0301116 W IL0301116 W IL 0301116W WO 2004059278 A3 WO2004059278 A3 WO 2004059278A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
screening
inflammatory drugs
selectin
small organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2003/001116
Other languages
French (fr)
Other versions
WO2004059278A2 (en
WO2004059278A8 (en
Inventor
Paul Gregor
Nicholas Harris
Juraj Koppel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rimonyx Pharmaceuticals Ltd
Original Assignee
Rimonyx Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rimonyx Pharmaceuticals Ltd filed Critical Rimonyx Pharmaceuticals Ltd
Priority to AU2003288698A priority Critical patent/AU2003288698A1/en
Priority to US10/541,099 priority patent/US20060275214A1/en
Priority to EP03780600A priority patent/EP1579214A4/en
Publication of WO2004059278A2 publication Critical patent/WO2004059278A2/en
Publication of WO2004059278A8 publication Critical patent/WO2004059278A8/en
Publication of WO2004059278A3 publication Critical patent/WO2004059278A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to methods for screening small organic compounds capable of inhibiting the interactions of glycosaminoglycans with effector cell adhesion molecules. Specifically, the present invention provides a method for screening of small organic compounds, the compounds inhibit the interaction of heparin with L-selectin or P-selectin. The compounds identified by the methods of the invention are useful for treating inflammatory disorders, autoimmune diseases and cancer.
PCT/IL2003/001116 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof Ceased WO2004059278A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003288698A AU2003288698A1 (en) 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof
US10/541,099 US20060275214A1 (en) 2003-12-30 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof
EP03780600A EP1579214A4 (en) 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL15376202A IL153762A0 (en) 2002-12-31 2002-12-31 Methods of screening for anti-inflammatory drugs and use thereof
IL153762 2002-12-31

Publications (3)

Publication Number Publication Date
WO2004059278A2 WO2004059278A2 (en) 2004-07-15
WO2004059278A8 WO2004059278A8 (en) 2004-09-02
WO2004059278A3 true WO2004059278A3 (en) 2005-03-03

Family

ID=29798407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/001116 Ceased WO2004059278A2 (en) 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof

Country Status (4)

Country Link
EP (1) EP1579214A4 (en)
AU (1) AU2003288698A1 (en)
IL (1) IL153762A0 (en)
WO (1) WO2004059278A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045831A1 (en) * 1999-02-02 2000-08-10 Thomas Jefferson University Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2658092A (en) * 1991-09-12 1993-04-05 Novo Nordisk A/S A method of screening for inhibitors of heparin-binding protein
GB0119476D0 (en) * 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045831A1 (en) * 1999-02-02 2000-08-10 Thomas Jefferson University Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DIAMOND ET AL.: "Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1)", J. CELL. BIOL., vol. 130, no. 6, 1995, pages 1473 - 1482, XP002982966 *
HAUGEN ET AL.: "A cell-surface heparan sulfate proteoglycan mediates neural cell adhesion and spreading on a defined sequence from the C-terminal cell and heparin binding domain of fibronectin, FN-C/H II", J. NEUROSCI., vol. 12, no. 7, July 1992 (1992-07-01), pages 2597 - 2608, XP008041842 *
KOENIG ET AL.: "Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents", J. CLIN. INVEST., vol. 101, no. 4, 15 February 1998 (1998-02-15), pages 877 - 889, XP002982965 *
NELSON ET AL.: "Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation", BLOOD, vol. 82, no. 11, 1 December 1993 (1993-12-01), pages 3253 - 3258, XP000573628 *
PETER ET AL.: "Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18)", CIRCULATION, vol. 100, no. 14, 5 October 1999 (1999-10-05), pages 1533 - 1539, XP002982967 *

Also Published As

Publication number Publication date
EP1579214A2 (en) 2005-09-28
AU2003288698A8 (en) 2004-07-22
WO2004059278A2 (en) 2004-07-15
EP1579214A4 (en) 2008-08-27
IL153762A0 (en) 2003-07-06
AU2003288698A1 (en) 2004-07-22
WO2004059278A8 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
WO2007022225A3 (en) Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2006037537A3 (en) D-pyranosyl-substituted phenyls, medicaments containing said compounds, use thereof, and method for the production thereof
WO2008138126A8 (en) Bicyclic pyrimidine derivatives as calcium channel blockers
WO2004078144A3 (en) Diphenylethylene compounds and uses thereof
WO2004098494A3 (en) Compounds, compositions, and methods
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2005116086A3 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
AU2003283839A1 (en) Heteropolyacid and/or its salt supported catalyst, production process of the catalyst and production process of compound using the catalyst
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
AU2003263753A1 (en) Molecular weight reduction of polysaccharides by electron beams
AU2006254902A8 (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
WO2009060835A1 (en) Novel ubiquilin-binding small molecule
WO2007098203A3 (en) Conductive polymers from precursor polymers, method of making, and use thereof
TW200714600A (en) Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
AU2003277574A1 (en) Depolymerization process
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
AU2003250753A1 (en) Method for producing organic compounds containing poly-dopo, and the use of the same
AU2003261657A1 (en) Promoter for the production of hyaluronic acid containing ginsenoside compound k
WO2006066950A3 (en) Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
AU2002332140A1 (en) Process for reducing the toxicity of hydrocarbons
WO2006026747A3 (en) Diphenylethylene compounds and uses thereof
NL1025044A1 (en) Bicyclic derivatives for the treatment of abnormal cell growth.
WO2004059278A3 (en) Methods of screening for anti-inflammatory drugs and use thereof
MX2007002833A (en) Alkylidene tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2004 UNDER (71) THE ADDRESS SHOULD READ "KIRYATWEIZMANN SCIENCE PARK"

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003780600

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003780600

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006275214

Country of ref document: US

Ref document number: 10541099

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10541099

Country of ref document: US